TREATMENT OF RENAL CARCINOMA IN A BINTURONG (ARCTICTIS BINTURONG) WITH NEPHRECTOMY AND A TYROSINE KINASE INHIBITOR

被引:1
|
作者
Thompson, Kimberly A. [1 ]
Patterson, Jon [2 ]
Fitzgerald, Scott D. [2 ]
Needle, David [2 ,3 ]
Harrison, Tara [1 ,4 ]
机构
[1] Michigan State Univ, Coll Vet Med, 784 Wilson Rd, E Lansing, MI 48824 USA
[2] Michigan State Univ, Diagnost Ctr Populat & Anim Hlth, Coll Vet Med, 4125 Beaumont Rd, Lansing, MI 48824 USA
[3] Univ New Hampshire, New Hampshire Vet Diagnost Lab, 21 Bot Lane, Durham, NH 03824 USA
[4] North Carolina State Univ, Dept Clin Sci, 1060 William Moore Dr, Raleigh, NC 27607 USA
关键词
Arctictis binturong; binturong; nephrectomy; renal adenocarcinoma; toceranib phosphate; tyrosinekinase inhibitor; CELL CARCINOMA; HYPERCALCEMIA; CANINE;
D O I
10.1638/2015-0285.1
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
A 13-yr-old female binturong (Arctictis binturong) presented with a 1 wk history of decreased appetite. The animal was thin, with hypercalcemia (calcium 12.2 mg/dl). A right renal mass was identified on ultrasound and removed via nephrectomy. Histopathology indicated a renal adenocarcinoma. Treatment with toceranib phosphate, a tyrosine-kinase inhibitor, was initiated and well tolerated by the animal. Four months after initial diagnosis radiographs indicated metastases to the lungs and the animal was euthanized. Necropsy revealed disseminated adenocarcinoma. Although treatment did not prevent metastasis, it was minimally invasive and well tolerated by the animal with minimal side effects. Review of records at the institution revealed that the cause of death for the primary case's dam and sire was disseminated renal carcinoma. These cases suggest that there may be a hereditary component to development of renal neoplasia in binturongs. Renal carcinoma should be considered an aggressive neoplasia in binturongs with a poor prognosis.
引用
收藏
页码:1109 / 1113
页数:5
相关论文
共 50 条
  • [21] Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
    Hailiang Zhang
    Lin Bai
    Xin-Qiang Wu
    Xi Tian
    Jinwen Feng
    Xiaohui Wu
    Guo-Hai Shi
    Xiaoru Pei
    Jiacheng Lyu
    Guojian Yang
    Yang Liu
    Wenhao Xu
    Aihetaimujiang Anwaier
    Yu Zhu
    Da-Long Cao
    Fujiang Xu
    Yue Wang
    Hua-Lei Gan
    Meng-Hong Sun
    Jian-Yuan Zhao
    Yuanyuan Qu
    Dingwei Ye
    Chen Ding
    Nature Communications, 14
  • [22] Pazopanib: An Oral Multitargeted Tyrosine Kinase Inhibitor for Use in Renal Cell Carcinoma
    LaPlant, Kourtney D.
    Louzon, Paige D.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (06) : 1054 - 1060
  • [23] Adjuvant therapy in renal cell carcinoma: Tyrosine kinase inhibitor versus immune checkpoint inhibitor
    Zhou, Qingbo
    Liu, Jianjiang
    Xie, Shaoqin
    MEDICINE, 2024, 103 (22) : E38329
  • [24] Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
    Zhang, Hailiang
    Bai, Lin
    Wu, Xin-Qiang
    Tian, Xi
    Feng, Jinwen
    Wu, Xiaohui
    Shi, Guo-Hai
    Pei, Xiaoru
    Lyu, Jiacheng
    Yang, Guojian
    Liu, Yang
    Xu, Wenhao
    Anwaier, Aihetaimujiang
    Zhu, Yu
    Cao, Da-Long
    Xu, Fujiang
    Wang, Yue
    Gan, Hua-Lei
    Sun, Meng-Hong
    Zhao, Jian-Yuan
    Qu, Yuanyuan
    Ye, Dingwei
    Ding, Chen
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [25] Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment
    Kaneko, Shun
    Tsuchiya, Kaoru
    Yasui, Yutaka
    Tanaka, Yuki
    Inada, Kento
    Ishido, Shun
    Kirino, Sakura
    Yamashita, Koji
    Hayakawa, Yuka
    Nobusawa, Tsubasa
    Matsumoto, Hiroaki
    Kakegawa, Tatsuya
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Tamaki, Nobuharu
    Takahashi, Yuka
    Nakanishi, Hiroyuki
    Irie, Takumi
    Ariizumi, Shun-Ichi
    Kurosaki, Masayuki
    Izumi, Namiki
    JGH OPEN, 2022, 6 (05): : 301 - 308
  • [26] Treatment of hepatocellular carcinoma (HCC) with the tyrosine kinase inhibitor Imatinib.
    Armbrust, T
    Baumhoer, D
    Werner, J
    Schleyer, E
    Ramadori, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 360S - 360S
  • [27] Ongoing Screening and Treatment to Potentially Reduce Tyrosine Kinase Inhibitor-Related Fatigue in Renal Cell Carcinoma
    Anand, Deepa
    Escalante, Carmen P.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2015, 50 (01) : 108 - 117
  • [28] Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report
    Azuma, Takeshi
    Sugihara, Tohru
    Honda, Sachi
    Yoshizaki, Uran
    Nimi, Fusako
    Tsuru, Ibuki
    Kume, Haruki
    ONCOLOGY LETTERS, 2019, 17 (04) : 4011 - 4015
  • [29] Tyrosine kinase inhibitor treatment for renal cell carcinoma with inferior vena cava tumour thrombus: a quantitative summary
    Klatte, Tobias
    Welsh, Sarah J. J.
    Riddick, Antony C. P.
    Karam, Jose A.
    Stewart, Grant D. D.
    BJU INTERNATIONAL, 2023, 131 (05) : 566 - 568
  • [30] Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
    Mário Fontes-Sousa
    Helena Magalhães
    Alicia Oliveira
    Filipa Carneiro
    Filipa Palma dos Reis
    Pedro Silvestre Madeira
    Sara Meireles
    Advances in Therapy, 2022, 39 : 1107 - 1125